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Aim of this prospective study is to evaluate the expression of 
HIF-1 after RT and correlate it with the development of 
rectal mucosal angiectasias and bleeding.  
 
Material and Methods: Patients with histological proof of 
prostate cancer without distant metastases, undergoing a 
standard course of external beam radiation therapy (3D-RT), 
were considered eligible. Each patient underwent a 
rectosigmoidoscopy with bioptic sampling prior to and one 
month and one year after RT. The development of rectal 
mucosal angiectasias was graded according to the Vienna 
Rectoscopy Score (VRS). HIF-1 was evaluated by 
immunohistochemistry and western blot analysis; the mean 
number of blood vessels per field was also assessed. 
Radiation-induced side effects (e.g. rectal bleeding) were 
recorded during follow-up visits.  
 
Results: Thirty-one patients were enrolled (median age 72 
years, IQR 67-75). After the end of a median follow-up of 
19.8 months (IQR 18.4-20.9), 10 patients (32.3%) developed 
rectal bleeding needing intervention. All these patients 
presented a grade II or III VRS (p=0.03). The difference in the 
mean number of blood vessels between bleeders and not 
bleeders was not significantly different (p=0.47). The 
expression of HIF1 in bleeding patients was down regulated in 
2 cases, unchanged in 3 and up regulated in 4 cases (p>0.99); 
in one case it was not feasible to determine the expression. 
There was no correlation between the expression of HIF1 and 
the VRS.  
 
Conclusion: The expression of HIF1 does not correlate with 
the development of rectal mucosal angiectasias and bleeding 
in patients irradiated for prostate cancer. 
 
Poster: Radiobiology track: Biomarkers and biological 
imaging  
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Purpose or Objective: Subventricular zone-infiltrating (SVZ-
infiltrating) glioblastomas (GBMs) with subependymal spreads 
along ventricle walls are associated with decreased patient 
survival. The heterogeneity in patient survival and recurrence 
patterns of GBM with SVZ infiltration might be related to 
neuronal therapy resistant stem cells, located in the SVZ. It 
has not been systematically investigated if specific molecular 
genetic patterns of SVZ-infiltrating GBMs exist, and therefore 
are responsible for the unfavorable course after 
chemoradiation. 
 
Material and Methods: The current study assessed the 
molecularbiologic profile of 55 primary GBM cases that 
underwent chemoradiation. GBMs with SVZ infiltration and 
subependymal tumor spread (n = 24; 43.6 %) and peripherally 
located GBMs (n = 31; 56.4 %) were included. Genome 
methylation patterns were determined and copy number 
profiling was performed using an Illumina Infinium 
HumanMethylation450K (450K) Array, and the prognostic 
influence on progression and survival was evaluated. 
 
Results: The majority of patients showed the characteristics 
of a “classic” GBM subtype, independent of the tumor 
localization in regard of the SVZ, demonstrating a 
chromosome 7 gain and chromosome 10 loss, as well as 
deletion of Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A) 
and amplification of Epidermal Growth Factor Receptor 
(EGFR). Second, RTK I subtype, showing Platelet-Derived 
Growth Factor Receptor Alpha (PDGFRA) amplifications, 
could be detected equally in both groups. However, SVZ-
infiltrating GBMs with subependymal spreading showed a 
decreased overall survival (OS) compared to their peripheral 
counterparts. 
 
 
 
Figure: Genome wide copy number profiling of a classic 
primary gliolblastoma with chromosome 7 gain and 
chromosome 10 loss  
 
Conclusion: Genome methylation patterns were distributed 
independently of tumor localization in regard of the SVZ, 
suggesting that the biological entities in both GBM groups are 
identical. However, survival rates of GBMs with proximity to 
the SVZ were inferior and therefore the central localization 
seems to be responsible for the poor clinical courses. 
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Purpose or Objective: Evidence to support a role for the 
antidiabetic drug metformin in the prevention and treatment 
of cancer has emerged over the last decade. In particular, 
recent studies demonstrate that metformin enhances tumor 
response to radiation in experimental models. Metformin may 
therefore be of utility for nondiabetic cancer patients 
treated with radiation therapy. Despite being in clinical use 
for almost 60 years, the underlying mechanisms for 
metformins action remain elusive. We have therefore applied 
a novel PET-tracer, [11C]-metformin, to determine the 
uptake mechanism and elimination of the drug in vitro and in 
vivo. 
 
Material and Methods: To verify transporter-mediated 
uptake of metformin in tumor cells, a selection of cell lines 
were incubated with [11C]-metformin in the absence or 
presence of blocking unlabelled metformin. Two tumor 
models A549 (lung) and SiHa (cervix) was chosen for in vivo 
experiments. Mice bearing subcutaneous tumors in the lower 
back were administered ~10 MBq [11C]-metformin and 
dynamically PET scanned for 90 minutes. As a “proof of 
principle” experiments using PET/CT with [11C]-metformin 
organ specific uptake of [11C]-metformin was determined in 
healthy humans. Dynamic whole-body PET was performed on 
four healthy volunteers (2 male). Two minutes before scan 
start, a bolus injection of ~200 MBq [11C]-metformin was 
injected and five consecutive whole-body scans with 
increasing frame durations were obtained: 1, 1.5, 2, 2.5 and 
3 minutes per bed position. Time intervals for the PET scans 
were 2-8, 9-18, 19-32, 33-48 and 49-67 minutes (see figure 
1). Source organs for the dosimetry calculations were the 
liver, kidneys, salivary glands and the bladder. 
Results: In vitro metformin uptake varied widely but a high 
and inhibitable uptake was observed in A549 and SiHa cells. 
